Immunotherapy plus chemotherapy for advanced biliary tract cancer
Part of Cancer, Digestive system clinical trials.
This study tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus chemotherapy and a targeted drug (lenvatinib) for biliary tract cancer that has spread or cannot be surgically removed. The goal is to slow cancer growth in patients whose cancer has progressed after one prior treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Confirmed biliary tract cancer (gallbladder, bile duct, or ampullary) that is unresectable or has spread to other parts of the body
- Previously received one line of chemotherapy containing platinum, gemcitabine, or fluoropyrimidine drugs
- Age 18–70 years with good overall health (ECOG performance status 0–1) and life expectancy of at least 12 weeks
- At least one measurable tumor visible on CT or MRI scan (10 mm or larger)
- Normal blood counts, liver and kidney function, and heart function (LVEF ≥60%)
- No brain tumors, significant heart disease, uncontrolled high blood pressure, or active bleeding problems
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of three drugs (anlotinib, nab-paclitaxel, and S-1) for people with advanced bile duct or gallbladder cancer that has progressed after first-line chemotherapy. The goal is to see if this combination can help control the cancer better than standard second-line options.
This study tests a combination of freezing the tumor (cryoablation), an investigational immunotherapy (QL1706), and a targeted therapy pill (lenvatinib) for people with advanced bile duct cancer that has progressed after initial treatment. The goal is to see if this new combination can help control the cancer and improve outcomes.
This trial tests a new immunotherapy drug combined with standard chemotherapy as a first treatment for advanced bile duct or gallbladder cancer. It may help your immune system fight the cancer while chemotherapy attacks the tumor directly.
This study tests whether adding another drug (lenvatinib or chemotherapy) to the immunotherapy drug pembrolizumab works better than pembrolizumab alone for advanced bile duct or gallbladder cancer that has not been treated before. It aims to find a more effective first treatment option.
This study tests a combination of three drugs (gemcitabine, cisplatin, nab-paclitaxel) plus an immunotherapy (tislelizumab) for people with advanced biliary tract cancer who haven't had treatment yet. The goal is to see if this cocktail shrinks tumors better than standard care.
This study tests a combination of four drugs—two immunotherapy drugs (iparomlimab and toripalimab), a targeted therapy (bevacizumab), and chemotherapy—as a first-line treatment for advanced biliary tract cancer (cancer of the bile ducts or gallbladder). The goal is to see if this combination can shrink tumors and help patients live longer.
Hear when a new Second-Line Therapy for Unresectable or Metastatic Biliary Tract Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.